Welcome to our dedicated page for Celularity news (Ticker: CELUW), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc (NASDAQ: CELUW) drives innovation in placental-derived cell therapies and regenerative biomaterials, targeting cancer, immune disorders, and degenerative diseases. This page aggregates all verified news and press releases from this clinical-stage biotechnology leader.
Access real-time updates on clinical trial progress, financial disclosures, and strategic partnerships. Investors and researchers will find essential announcements including:
• Clinical Developments: Phase updates for allogeneic NK cell therapies and CAR-T programs
• Financial Reports: Quarterly earnings and SEC filings
• Operational Milestones: Manufacturing expansions and regulatory submissions
• Research Collaborations: Partnerships with academic institutions and biopharma leaders
All content is sourced directly from Celularity’s investor relations and verified industry channels. Bookmark this page for efficient tracking of the company’s progress in advanced cell engineering and regenerative medicine solutions.
Celularity (Nasdaq: CELU), a regenerative medicine company, received a Nasdaq notice on May 21, 2024, for not filing its Q1 2024 Form 10-Q and 2023 Form 10-K on time. This puts Celularity in non-compliance with Nasdaq's listing requirements, but it doesn't affect the current trading of its stock and warrants. Celularity must submit a compliance plan by June 17, 2024, and has until October 14, 2024, to regain compliance if the plan is accepted. The company is working to complete its filings but cannot guarantee Nasdaq will accept the plan or that it will meet future requirements.
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to those derived from adult peripheral blood mononuclear cells (PBMCs). Key findings include longer telomeres and attenuated cytokine responses without loss of cytotoxicity. These advantages may lead to more effective and scalable CAR-T therapies. Dr. Robert Hariri, CEO of Celularity, emphasized the potential of their platform to deliver improved and durable allogeneic CAR-T products.
FAQ
What is the current stock price of Celularity (CELUW)?
